Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval

Yutaka Yamamoto 1
Ichiro Kawano 2
Hirotaka Iwase 1

1Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; 2Department of Surgery, Asahino General Hospital, Kumamoto, Japan

Abstract: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel formulation of paclitaxel that does not require solvents such as polyoxyethylated castor oil and ethanol. Use of these solvents has been associated with toxic response, including hypersensitivity reactions and prolonged sensory neuropathy, as well as a negative impact in relation to the therapeutic index of paclitaxel. nab-paclitaxel displays greater antitumor activity and less toxicity than solvent-base paclitaxel. In a phase I trial of single nab-paclitaxel, the maximum tolerated dose was 300 mg/m² with the dose limiting toxicities being sensory neuropathy, stomatitis, and superficial keratopathy. In the metastatic setting, a pivotal comparative randomized phase III study demonstrated that nab-paclitaxel (at 260 mg/m² over 30 minutes infusion without premedication every 3 weeks) mediated a superior objective response rate and prolonged time to progression compared with solvent-based paclitaxel (at 175 mg/m² over a 3-hour injection with standard premedication). The nab-paclitaxel-treated group showed a higher incidence of sensory neuropathy than the solvent-based paclitaxel group. However, these adverse side effects rapidly resolved after interruption of treatment and dose reduction. Weekly administration of nab-paclitaxel was also more active and displayed less toxicity compared with 100 mg/m² docetaxel given triweekly. Nab-paclitaxel has already been approved in 42 countries for the treatment of metastatic breast cancer previously treated with anthracycline, based on confirmation of the efficacy and manageable toxicity in the metastatic setting. This review summarizes the most relevant knowledge on nab-paclitaxel for treating breast cancer in terms of clinical usefulness including efficacy and safety of this new agent.

Keywords: nab-paclitaxel, breast cancer, toxicity profile

Introduction

Breast cancer in women is a major health problem worldwide, with approximately 1,150,000 new cases diagnosed and 410,000 deaths attributed to the disease in 2002. 1 Breast cancer is a heterogeneous disease in terms of gene expression, morphology, clinical course, and response to treatment. Gene expression profiling divides breast cancer into several subtypes including luminal, human epidermal growth factor receptor 2 (HER2)-enriched, basal-like, and normal-like subtypes. 2 Lumina A and B subtypes are also classified by expression levels of estrogen receptor (ER)-α and ER-α-related gene. Basal-like subtype is almost identical to triple-negative breast cancer which is defined as showing an absence of ER-α and progesterone receptor, and no protein overexpression or gene amplification of HER2. Luminal A subtype has better prognosis than luminal B, HER2-enriched and basal-like subtypes. Luminal and HER2-enriched subtypes have several effective therapeutic targets such as ER for endocrine therapy...
and HER2 for anti-HER2 therapy. Basal-like subtype has no effective therapeutic target at present. The response for cytotoxic agents also different according to tumor subtypes. HER2-enriched and basal-like subtypes are more responsive to chemotherapy than the luminal A subtype.3

Chemotherapy for patients with breast cancer is effective in not only reducing recurrence of this disease and improving survival in the adjuvant setting, but also in prolonging survival and improving quality of life in the metastatic setting.

The taxanes, such as paclitaxel and docetaxel, are one of the most active and widely used classes of cytotoxic agents in breast cancer treatment. Taxanes act through binding with tubulin and stabilizing nonfunctional microtubule bundles, leading to subsequent defects in mitotic spindle assembly, chromosome segregation and cell division, resulting in cell death.4,5 A meta-analysis showed that the addition of taxane to an anthracycline-based regimen in the adjuvant setting improved the disease-free survival and overall survival (OS) in patients with high-risk early stage breast cancer compared with an anthracycline-based regimen.6 Another meta-analysis in the metastatic setting showed that taxane and anthracycline were equivalent in terms of effects on response rate and OS, although the taxanes were significantly less efficacious than anthracyclines in relation to impact on progression-free survival (PFS).7 However, the conventionally used taxanes, paclitaxel and docetaxel, have several limitations for clinical use. For example, taxanes are poorly soluble in water due to hydrophobic properties, and they require solvents when used in clinical formulations. However, the use of solvents in the formulation of these therapeutic agents limits their clinical effectiveness, in that these vehicles induce toxic responses, such as hypersensitivity and peripheral neuropathy, and can reduce the extent of drug delivery to tumor.8

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, sold under the trade name Abraxane®; Celgene Corporation, Summit, NJ), which is a solvent-free form of paclitaxel, can potentially avoid these limitations. Nab-paclitaxel is widely approved for the treatment of metastatic breast cancer on the basis of results from pivotal trials showing that it has superior antitumor effects and improved tolerability than solvent-based paclitaxel.9 In this review, we focus on discussing the clinical usefulness, safety, and efficacy of nab-paclitaxel. To achieve our aim, we searched papers on nab-paclitaxel for treating breast cancer electronically, by hand, and through discussion with experts. We mainly used PubMed (from 1970 to 2011) to find published literature.

Development of nab-paclitaxel
Paclitaxel, a mitotic inhibitor which acts via microtubule stabilization, is isolated from the bark of the Pacific yew tree, Taxus brevifolia.10 and is widely used to treat several solid tumor types including breast, lung, and ovarian cancer.

Paclitaxel is highly insoluble in water, with formulation of this agent requiring emulsification with solvents, such as polyoxyethylated castor oil (Cremophor EL®: CrEL) and ethanol, to allow intravenous administration.11 Furthermore, solvent-based paclitaxel must be diluted 5- to 20- fold with normal saline or 5% dextrose solutions before intravenous administration.12

The solvents used in paclitaxel formulation are biologically and pharmacologically active in that they can lead to serious toxicities such as hypersensitivity reaction11 and peripheral neuropathy.13,14 CrEL promotes a plasticizer, di(2-ethylhexyl) phthalate (DEHP), which is released from standard intravenous tubing sets containing polyvinyl chloride. Thus the infusional fluid can contain leached DEHP, which subsequently stimulates histamine release and results in hypersensitivity reaction, including anaphylaxis. To offset this adverse response, a special infusion set (containing nonpolyvinyl chloride tubing with an in-line filter) must be used with prolonged infusion, as well as premedication with corticosteroids, antihistamine, and H2-blocker, when administering CrEL-paclitaxel infusion. Despite these precautions, this side effect still occurs at the level of minor reactions, such as flushing and rush, in 40% of treated patients, with life-threatening metastatic disease in 3% of treated patients.15

CrEL-paclitaxel induces peripheral sensory and motor neuropathy. Indeed, peripheral neuropathy is a dose-limiting factor for CrEL-paclitaxel, with the effect often being prolonged and irreversible. Such irreversible neuropathy is associated axonal degeneration, vesicular degeneration, and demyelination.16,17 In addition, CrEL has been shown to have a negative effect in relation to the antitumor properties of paclitaxel. The formation of CrEL micelles in the plasma compartment entraps paclitaxel, resulting in reduced drug clearance, nonlinear pharmacokinetics, and free drug fraction.15,18

These findings are strongly associated with the absence of a dose-dependent antitumor response in breast cancer patients treated with paclitaxel.19 Several developments have taken place in efforts to avoid the above-mentioned disadvantages of solvent-based taxanes. Nab-paclitaxel, which is CrEL-free, is a key example of such efforts.
The role of albumin as a drug delivery system and nab-paclitaxel

Albumin plays an important role in the delivery of hydrophobic molecules to target tissue. Albumin is a natural carrier of endogenous hydrophobic molecules such as vitamins, hormones, and other substances in the human circulation.\(^{20,21}\) Albumin binds these substrates reversibly in a noncovalent manner. Albumin is also associated with endothelial transcytosis of protein-bound and unbound plasma components through binding to a 60 kDa cell surface glycoprotein receptor (gp60) on the endothelial cell membrane. gp60 induces caveolin-1, resulting in internalization of the albumin-substrate complex into caveola, transcytotic vesicles, with substrates being subsequently delivered into tumor cells.\(^{22-26}\)

Nab-paclitaxel is prepared by high-pressure homogenization of paclitaxel in the presence of serum albumin, resulting in a colloidal suspension comprising nanoparticles of 130 nm on average, which prevent the risk of capillary blockage after intravenous infusion.\(^{27,28}\) Nab-paclitaxel consists of a lyophilized powder, which is reconstituted with 20 mL 0.9% sodium chloride solution before intravenous infusion. Each single-use vial contains 100 mg of paclitaxel and approximately 900 mg of human albumin. The final colloid solution contains 5 mg/mL of paclitaxel and approximately 45 mg/mL of albumin. Based upon in vivo study, it seems that the nab particles disperse into the individual albumin molecules with bound paclitaxel immediately after introduction into aqueous solution, as would occur after injection into the bloodstream.\(^{8}\)

Preclinical studies

Using athymic mice bearing human cancer xenografts, Desai et al demonstrated that the antitumor activity and toxicity profile of nab-paclitaxel was better than that of CrEL-paclitaxel.\(^{27}\) The lethal dose (LD)\(_{50}\) and maximum tolerated dose (MTD) for nab-paclitaxel and CrEL-paclitaxel were 47 and 30 mg/kg/day and 30 and 13.4 mg/kg/day, respectively. At equitoxic doses, nab-paclitaxel had significantly better antitumor effects including tumor-free survival, time to tumor recurrence (\(P = 0.004\)), tumor doubling time (\(P = 0.0015\)), and tumor volume (\(P = 0.009\)) compared with CrEL-paclitaxel. At an equal dose of paclitaxel, the level of intratumoral paclitaxel accumulation was higher in nab-paclitaxel-treated mice than those in receipt of CrEL-paclitaxel. The extent of endothelial binding and transcytosis of paclitaxel was significantly greater for nab-paclitaxel than CrEL-paclitaxel, with this difference being completely suppressed by an inhibitor of caveola-mediated transcytosis. CrEL also suppressed paclitaxel binding to endothelial cells and albumin. These findings indicated that nab-paclitaxel mediates greater intratumoral accumulation of paclitaxel and associated increased efficacy compared with CrEL-paclitaxel.

Pharmacokinetic study

The relevant pharmacokinetic parameters in several studies are shown in Table 1. In a phase I study of nab-paclitaxel administration over 30 minutes every 3 weeks in 19 patients with metastatic melanoma or breast cancer, the MTD was determined to be 300 mg/m\(^2\).\(^{28}\) The dose-limiting toxicities (DLTs) were sensory neuropathy (3 patients), stomatitis (2 patients), and superficial keratopathy (2 patients). No hypersensitivity reaction was observed despite no premedication such as corticosteroids and antihistamines. Nab-paclitaxel also showed linear pharmacokinetics. In more detail, plasma levels of paclitaxel declined in a biphasic manner after intravenous administration of nab-paclitaxel with a rapid first phase representing distribution to the peripheral tissue and the second slower phase representative of drug elimination. Sparreboom et al performed a comparative pharmacokinetics study of nab-paclitaxel (260 mg/m\(^2\) given as a 30-minute infusion) and CrEL-paclitaxel (175 mg/m\(^2\) given as a 180-minute infusion) in patients with metastatic breast, lung, and ovarian cancer.\(^{29}\) The maximum concentration of paclitaxel was 6.5-fold higher for nab-paclitaxel than for CrEL-paclitaxel. The mean area under the curve (AUC) from time zero to infinity and plasma terminal elimination rate for nab-paclitaxel was similar to that observed for CrEL-paclitaxel notwithstanding the differences in administration dose, resulting in similar elimination half-lives for paclitaxel in these two groups. However, the mean apparent total body clearance of the drug from plasma and the apparent volume of distribution during the terminal phase of paclitaxel after administration of nab-paclitaxel were both significantly higher than that seen after administration of CrEL-paclitaxel. This large volume of distribution (664 L/m\(^2\)) for nab-paclitaxel suggests extensive extravascular distribution and/or tissue binding of paclitaxel.

Gardner et al also conducted a pharmacokinetic study of nab-paclitaxel (260 mg/m\(^2\) given as a 30-minute infusion) compared with CrEL-paclitaxel (175 mg/m\(^2\) given as a 180-minute infusion).\(^{30}\) The mean fraction unbound of paclitaxel was significantly higher for nab-paclitaxel than CrEL-paclitaxel (0.063 ± 0.021 vs 0.024 ± 0.009; \(P < 0.001\)), although the total drug exposure was comparable between the two drug formulations. These findings are in agreement with the greater antitumor efficacy of nab-paclitaxel compared with that of CrEL-paclitaxel.
Another phase I study of nab-paclitaxel administration (30 minutes once a week for 3 weeks, followed by 1 week of rest) in 39 patients with advanced nonhematologic malignancies was conducted. In this case, the dose of nab-paclitaxel ranged from 80 to 200 mg/m². The MTDs for heavily and lightly pretreated patients were 100 mg/m² and 150 mg/m², respectively with the observed DLTs being grade 4 neutropenia and grade 3 peripheral neuropathy, respectively. Pharmacokinetics were also linear over the dose range of 80–200 mg/m².

There was no ethnic difference in the pharmacokinetics of nab-paclitaxel between Westerners and Japanese.

### Clinical efficacy in metastatic setting

#### Single agent nab-paclitaxel

The tumor responses for single agent nab-paclitaxel in several clinical trials are shown in Table 2(a). Ibrahim et al conducted a phase II trial in 63 patients with metastatic breast cancer, who were treated with 300 mg/m² nab-paclitaxel over 30 minutes every 3 weeks. Seventy-six percent of patients received prior chemotherapy, with 38% of patients having received such treatment in the metastatic setting. Overall response rates were 48% (95% CI, 35.3% to 60.0%) while the response rate in patients who had not received prior chemotherapy was 64% (95% CI, 49.0% to 79.2%).

The median times to disease progression and median survival were 26.6 and 63.6 weeks, respectively.

Blum et al performed another phase II study of weekly nab-paclitaxel in patients with metastatic breast cancer, which had been heavily pretreated with taxanes. In total, 181 patients were treated with either 100 mg/m² (n = 106) or 125 mg/m² (n = 75) nab-paclitaxel on days 1, 8, and 15, followed by 1 week of rest, every 28 days. The response rates of the 100 mg/m² and 125 mg/m² cohorts were 14% and 16%, respectively. The rates of disease control (objective response and stable disease ≥ 16 weeks) in these two cohorts were 26% and 37%, respectively. Median PFS and OS were also not significantly different between these two cohorts (100 mg/m²: PFS 3.0 months and OS 9.2 months, 125 mg/m²: PFS 3.5 months and OS 9.1 months). Weekly administration of 100 mg/m² nab-paclitaxel showed the same antitumor activity as 125 mg/m², with the benefit of a more favorable toxicity profile in patients with metastatic disease that progressed after previous taxane treatment.

A pivotal international, randomized, open-label phase III trial was conducted to compare the activity and safety of nab-paclitaxel with CrEL-paclitaxel in metastatic breast cancer patients. Forty-six patients were randomized to nab-paclitaxel (260 mg/m² over a 30-minute infusion) without premedication or CrEL-paclitaxel (175 mg/m² over a 3-hour infusion) with standard premedication. Inclusion criteria

### Table 1 Pharmacokinetic parameters for nab-paclitaxel and CrEL-paclitaxel

<table>
<thead>
<tr>
<th>Authors</th>
<th>Drug</th>
<th>n</th>
<th>Dose (mg/m²)</th>
<th>Infusion time (min.)</th>
<th>Cmax (ng/mL)</th>
<th>AUC0-∞ (ng/h/mL)</th>
<th>t1/2 (h)</th>
<th>CL (L/h/m²)</th>
<th>Vz (L/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibrahim et al</td>
<td>nab-P</td>
<td>3</td>
<td>200</td>
<td>30</td>
<td>7757</td>
<td>9613</td>
<td>13.4</td>
<td>17.7</td>
<td>370</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(35%)</td>
<td>(20%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5</td>
<td>300</td>
<td>30</td>
<td>13520</td>
<td>17610</td>
<td>14.6</td>
<td>17.7</td>
<td>370</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(7%)</td>
<td>(21%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nyman et al</td>
<td>nab-P</td>
<td>6</td>
<td>100</td>
<td>30</td>
<td>4513</td>
<td>4311</td>
<td>18.2</td>
<td>25.7</td>
<td>667</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2002)</td>
<td>(1557)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>150</td>
<td>30</td>
<td>8433</td>
<td>7107</td>
<td>14.8</td>
<td>27.4</td>
<td>617</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(4816)</td>
<td>(4231)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparreboom et al</td>
<td>nab-P</td>
<td>14</td>
<td>260</td>
<td>30</td>
<td>22969</td>
<td>14789</td>
<td>21.6</td>
<td>21.1</td>
<td>664</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(113%)</td>
<td>(45%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CreL-P</td>
<td>12</td>
<td>175</td>
<td>180</td>
<td>3543</td>
<td>12603</td>
<td>20.5</td>
<td>14.8</td>
<td>433</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(57%)</td>
<td>(21%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gardner et al</td>
<td>nab-P</td>
<td>14</td>
<td>260</td>
<td>30</td>
<td>19556</td>
<td>20325</td>
<td>20.0</td>
<td>13.2</td>
<td>375</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(36%)</td>
<td>(20%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CreL-P</td>
<td>14</td>
<td>175</td>
<td>180</td>
<td>5128</td>
<td>20821</td>
<td>20.9</td>
<td>8.9</td>
<td>271</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(33%)</td>
<td>(26%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yamada et al</td>
<td>nab-P</td>
<td>6</td>
<td>260</td>
<td>30</td>
<td>11635</td>
<td>14593</td>
<td>19.5</td>
<td>18.1</td>
<td>510</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(13%)</td>
<td>(14%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: The numerical values show mean and coefficient of variation; *standard deviation.

Abbreviations: n, number of patients; Cmax, maximum or peak concentration; AUC0-∞, area under the whole blood/plasma concentration-time curve from time 0 to time infinity; CL, total body clearance; Vz, volume of distribution; nab-P, nab-paclitaxel; CreL-P, Cremophor EL®-paclitaxel.
Table 2 Phase II and III trials with nab-paclitaxel for metastatic breast cancer

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study design and setting</th>
<th>Treatment schedule</th>
<th>No. of pts</th>
<th>ORR (95% CI)</th>
<th>CBR (95% CI)</th>
<th>TTP/PFS (95% CI)</th>
<th>OS (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a) Single agent nab-paclitaxel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibrahim et al</td>
<td>II</td>
<td>nab-P 300 mg/m², q3w</td>
<td>63</td>
<td>48% (35%–60%)</td>
<td>NR</td>
<td>26.6 W</td>
<td>63.6 W</td>
</tr>
<tr>
<td>Blum et al</td>
<td>II</td>
<td>nab-P 300 mg/m², q4w (D1,8,15)</td>
<td>106</td>
<td>14% (8%–20%)</td>
<td>12% (18%–35%)</td>
<td>3 M</td>
<td>9.2 M</td>
</tr>
<tr>
<td>Gradishar et al</td>
<td>III</td>
<td>Arm 1: nab-P 260 mg/m², q3w</td>
<td>229</td>
<td>33% (27%–39%)</td>
<td>NR</td>
<td>23.0 W</td>
<td>65.0 W</td>
</tr>
<tr>
<td>Guan et al</td>
<td>III</td>
<td>Arm 1: nab-P 260 mg/m², q3w</td>
<td>105</td>
<td>54%</td>
<td>NR</td>
<td>7.6 M</td>
<td></td>
</tr>
<tr>
<td>Gradishar et al</td>
<td>III, 1st line</td>
<td>Arm 1: nab-P 300 mg/m², q3w</td>
<td>76</td>
<td>37% (26%–48%)</td>
<td>68% (58%–79%)</td>
<td>11.0 M (7.3–15.0 M)</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Arm 2: nab-P 100 mg/m², qw</td>
<td>76</td>
<td>45% (34%–56%)</td>
<td>75% (65%–85%)</td>
<td>12.8 M (9.0–14.7 M)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arm 3: nab-P 150 mg/m², qw</td>
<td>74</td>
<td>49% (37%–60%)</td>
<td>80% (71%–89%)</td>
<td>12.9 M (10.9–16.6 M)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arm 4: DOC 100 mg/m², q3w</td>
<td>74</td>
<td>35% (24%–46%)</td>
<td>58% (47%–69%)</td>
<td>7.5 M (7.2–9.0 M)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P = 0.224</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P = 0.118</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mirtsching et al</td>
<td>II, HER2-1st line</td>
<td>nab-P 125 mg/m² (D1,8,15), q4w</td>
<td>42</td>
<td>38% (30%–75%)</td>
<td>67%</td>
<td>12.8 M</td>
<td>27.3 M</td>
</tr>
<tr>
<td><strong>b) nab-paclitaxel in combination with other cytotoxic agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roy et al</td>
<td>II, 1st line</td>
<td>nab-P 125 mg/m² + GEM 1000 mg/m² q3w (D1,8)</td>
<td>50</td>
<td>50% (36%–64%)</td>
<td>NR</td>
<td>7.9 M (5.4–10.0 M)</td>
<td>Not reached</td>
</tr>
<tr>
<td>Somer et al</td>
<td>II</td>
<td>nab-P 125 mg/m² (D1,8) + CAPE 1650 mg/m²/day (D1–14), q3w (D1,8)</td>
<td>38</td>
<td>48%</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td><strong>c) nab-paclitaxel in combination with molecular-targeted agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conlin et al</td>
<td>II, HER2+, 1st line</td>
<td>nab-P 125 mg/m² (D1,8,15) + CBDCA AUC 2 (D1,8,15) + Tras 2 mg/kg (D1,8,15,22), q4w</td>
<td>32</td>
<td>63% (46%–79%)</td>
<td>81%</td>
<td>16.6 M (7.5–26.5 M)</td>
<td>NR</td>
</tr>
<tr>
<td>Mirtsching et al</td>
<td>II, HER2+ 1st line</td>
<td>nab-P 125 mg/m² (D1,8,15) + Tras 2 mg/kg (D1,8,15,22), q4w</td>
<td>21</td>
<td>52% (30%–75%)</td>
<td>71%</td>
<td>18.7 M</td>
<td>36.8 M</td>
</tr>
<tr>
<td>Danso et al</td>
<td>II, HER2-, 1st line</td>
<td>nab-P 125 mg/m² (D1,8,15) + Bev 10 mg/kg (D1,15), q4w</td>
<td>27</td>
<td>30%</td>
<td>NR</td>
<td>9.2 M (5.3–16.1 M)</td>
<td>NR</td>
</tr>
<tr>
<td>Lobo et al</td>
<td>II, HER2-, 1st line</td>
<td>nab-P 150 mg/m² + GEM 1500 mg/m² + Bev 10 mg/kg q4w (D1,15)</td>
<td>28</td>
<td>76%</td>
<td>93% (77%–99%)</td>
<td>10.4 M (5.6–15.2 M)</td>
<td>18 M survival rate: 77%</td>
</tr>
<tr>
<td>Conlin et al</td>
<td>II, HER2-, 1st line</td>
<td>nab-P 125 mg/m² + Bev 15 mg/kg, q3w</td>
<td>73</td>
<td>44% (33%–55%)</td>
<td>NR</td>
<td>7.7 M (7.0–10.3 M)</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Arm 2: nab-P 260 mg/m² + G-CSF + Bev 10 mg/kg, q2w</td>
<td>54</td>
<td>39% (26%–52%)</td>
<td>NR</td>
<td>6.3 M (5.4–7.9 M)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arm 3: nab-P 130 mg/m² qw + Bev 10 mg/kg, q2w</td>
<td>80</td>
<td>46% (35%–57%)</td>
<td>NR</td>
<td>9.0 M (7.3–14.2 M)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: *No. of patients with metastatic breast cancer that progressed with previous taxane therapy; †arm 2 closed early due to unacceptable toxicities.

Abbreviations: nab-P, nab-paclitaxel; CreL-P, Cremophor EL®-paclitaxel; No., number; ORR, objective response rate; CBR, clinical benefit rate; TTP, time to progression; PFS, progression-free survival; OS, overall survival; CI, confidence interval; q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; qw, every week; NR, not recorded; M, month or months; W, week or weeks; ns, not significant; DOC, docetaxel; GEM, gemcitabine; CAPE, capecitabine; CBP, carboplatin; AUC, area under the curve; Tras, trastuzumab; Bev, bevacizumab; G-CSF, granulocyte-colony stimulating factor.
included no receipt of taxane for metastatic disease and no relapse with metastatic disease within 1 year of adjuvant taxane therapy. The objective response rate (ORR) and median time to progression (TTP) were significantly higher in nab-paclitaxel-treated patients than those receiving CrEL-paclitaxel (ORR: nab-paclitaxel 33% vs CrEL-paclitaxel 19%; \( P = 0.001 \), TTP: nab-paclitaxel 23.0 weeks vs CrEL-paclitaxel 16.9 weeks; hazard ratio [HR] = 0.75, \( P = 0.001 \)). Maximum responses occurred by cycle 3 in 91% of responders in the nab-paclitaxel group and in 81% of responders in the CrEL-paclitaxel group. The OS in the nab-paclitaxel group was greater than that in CrEL-paclitaxel group (65.0 weeks vs 55.7 weeks, respectively), but this did not reach statistical significance (\( P = 0.374 \)). This trial showed that nab-paclitaxel has superior clinical benefit including greater efficacy and a favorable safety profile without pre-medication compared with CrEL-paclitaxel.

A randomized phase II study compared nab-paclitaxel administered triweekly and weekly with triweekly docetaxel as first-line treatment for metastatic breast cancer. Nab-paclitaxel 125 mg/m\(^2\) was administered triweekly every 3 weeks, 100 mg/m\(^2\) weekly for 3 out of 4 weeks, 150 mg/m\(^2\) weekly for 3 out of 4 weeks, or docetaxel 100 mg/m\(^2\) every 3 weeks. Nab-paclitaxel, given as a weekly administration of 150 mg/m\(^2\), showed significantly greater PFS than 100 mg/m\(^2\) docetaxel given triweekly (12.9 vs 7.5 months, respectively; \( P = 0.0065 \)). Weekly nab-paclitaxel, regardless of dose, demonstrated a greater ORR than docetaxel (nab-paclitaxel 100 mg/m\(^2\) 45%, 150 mg/m\(^2\) 49%, docetaxel 35%), but this did not reach statistical significance. On the other hand, the disease control rate was significantly greater for patients treated with either dose of weekly nab-paclitaxel compared with docetaxel (100 mg/m\(^2\) nab-paclitaxel 75%, 150 mg/m\(^2\) 80%, docetaxel 58%, 100 mg/m\(^2\) nab-paclitaxel vs docetaxel; \( P = 0.009 \), 150 mg/m\(^2\) nab-paclitaxel vs docetaxel; \( P = 0.017 \)). No difference between 300 mg/m\(^2\) nab-paclitaxel given triweekly, and docetaxel treatment, was observed in terms of PFS and OS. This trial in the first-line metastatic setting showed superior efficacy and safety for weekly, especially 150 mg/m\(^2\), nab-paclitaxel compared with triweekly administered docetaxel.

Nab-paclitaxel in combination with cytotoxic agents

Tumor responses of nab-paclitaxel in combination with cytotoxic agents are listed in Table 2(b). Roy et al reported on a phase II trial of nab-paclitaxel and gemcitabine combination therapy in patients with previously untreated metastatic breast cancer. Fifty patients received 125 mg/m\(^2\) nab-paclitaxel and 1000 mg/m\(^2\) gemcitabine on days 1 and 8 every 21 days. The rates of complete response (CR) and partial response (PR) were 8% and 42%, respectively. The median PFS was 7.9 months (95% CI 5.4 to 10 months), with PFS and OS at 6 months being 60% (95% CI 48% to 76%) and 92% (95% CI 85% to 100%), respectively.

A phase II trial of nab-paclitaxel and bevacizumab combination therapy in the first-line treatment of metastatic breast cancer has also been reported. In this case, 50 patients were treated with 125 mg/m\(^2\) nab-paclitaxel on days 1, 8, and 1650 mg/m\(^2\) bevacizumab twice a day on days 1–14 every 3 weeks. Of the 38 patients available for analysis of response, the ORR was 47.5%; PR rate was 39.5%, and the CR rate was 8%.

Nab-paclitaxel in combination with molecularly-targeted agents

Taxane in combination with molecularly targeted therapies, such as trastuzumab and bevacizumab, mediates a greater antitumor effect with acceptable toxicity profiles in the metastatic setting compared with taxane treatment alone. Antitumor effects of nab-paclitaxel in combination with molecular-targeted agents are shown in Table 2(c). The US Oncology Research Network conducted multi-institutional and open-label phase II trials for patients with HER2-negative metastatic breast cancer. Patients were treated with weekly 125 mg/m\(^2\) nab-paclitaxel infusion over 30 minutes on days 1, 8, and 15, and 10 mg/kg bevacizumab on day 1 of a 28-day cycle as first-line chemotherapy. Of the 49 patients enrolled, 27 were evaluable for response. The confirmed ORR was 30% and the proportion of patients with stable disease >16 weeks was 22%. The median PFS was 9.2 months (95% CI, 5.3 to 16.1 months). Lobo et al also reported on a single-center and open-label phase II study to examine the efficacy and safety of nab-paclitaxel, in combination with gemcitabine and bevacizumab, in the context of first-line therapy in patients with HER2-negative metastatic breast cancer. Patients received 150 mg/m\(^2\) nab-paclitaxel, 1500 mg/m\(^2\) gemcitabine, and 10 mg/kg bevacizumab on days 1 and 15 of a 28-day cycle. Twenty-nine of the enrolled 30 patients were evaluable for antitumor response. The median PFS was 10.4 months (95% CI: 5.6–15.2 months), with the ORR and clinical benefit rate being 75.9% and 93.1%, respectively. Conlin et al conducted an open-label, randomized phase II study of nab-paclitaxel in combination with bevacizumab as first-line chemotherapy for patients with HER2-negative metastatic breast cancer. Patients were randomly assigned 260 mg/m\(^2\) nab-paclitaxel with 15 mg/kg bevacizumab every
3 weeks (arm A), 260 mg/m² nab-paclitaxel and 10 mg/kg bevacizumab every 2 weeks with pegfilgrastim (arm B), or 130 mg/m² nab-paclitaxel every week with 10 mg/kg bevacizumab every 2 weeks (arm C). Two-hundred and eight patients were randomized, with 202 patients administered the protocol treatment. There was no difference in ORR between these three groups (arm A: 42%, arm B: 42%, arm C: 41%). The median TTP was longer in arm C (9.2 months) than both arm B (6.4 months) and arm C (7.7 months, overall P = 0.028). Arm B was closed early due to an unacceptable toxicity profile, with evidence of significantly more grade ≥ 2 fatigue (arm A: 39%, arm B: 57%, arm C: 39%, P = 0.048) and bone pain (arm A: 10%, arm B: 19%, arm C: 4%, P = 0.024) as per the protocol-specified stopping rules. Although weekly nab-paclitaxel with bevacizumab for HER2-negative metastatic breast cancer showed the highest therapeutic index, sensory neuropathy was limiting. These data suggest that an adequate weekly regimen for metastatic disease, such as a 3 week on and 1 week rest schedule, should be examined comparatively.

For HER2-positive metastatic breast cancer, Conlin et al also conducted a multicenter phase II study to evaluate the efficacy and safety of weekly nab-paclitaxel in combination with carboplatin and weekly trastuzumab as first-line therapy. In this study, 33 patients were enrolled. Patients received 100 mg/m² nab-paclitaxel in combination with carboplatin at AUC = 2 at days 1, 8, and 15 of a 28-day cycle (in the first set of 13 patients) or at AUC = 6 at day 1 every 28 days (in the latter set of 19 patients). Trastuzumab was administered at 2 mg/kg weekly after a loading dose of 4 mg/kg. The ORR and clinical benefit rates (ORR and SD > 16 weeks) were 62.5% (95% CI 45.7% to 79.3%) and 81%, respectively. Nab-paclitaxel in combination with carboplatin and trastuzumab is highly active without increasing toxicities in breast cancer patients with HER2-positive disease.

Mitschting et al reported another phase II study of weekly 125 mg/m² nab-paclitaxel with or without weekly trastuzumab in first-line chemotherapy. HER2-positive patients received trastuzumab concurrently. Seventy-two patients were enrolled in this study. Of 50 HER2-negative or unknown patients and 22 HER2-positive patients, 42 and 21 patients were evaluable for tumor response. The objective response rates in HER2-negative or HER2-positive patients were 38.1% and 52.4%, respectively. The overall benefits (CR + PR + SD) in patients with HER2-negative or HER2-positive patients were 66.7% and 71.4%, respectively.

In the adjuvant and neoadjuvant setting

Adjuvant chemotherapy deeply contributes prolongation of survival after standard local treatment. Standard adjuvant regimens are anthracycline-containing regimen and taxane. However, survival benefit form adjuvant chemotherapy is still limited and patients receiving chemotherapy suffer chronic toxicities such as anthracycline-related cardiomyopathy and taxane-induced peripheral neuropathy. Nab-paclitaxel is more effective and less toxic than conventional taxanes, CrEL-paclitaxel and docetaxel, in randomized trials for metastatic breast cancer. Therefore, nab-paclitaxel is likely to be used in an adjuvant chemotherapy regimen. Several adjuvant trials of nab-paclitaxel have been conducted (Table 3).

Yardley et al conducted a pilot study in 62 patients with node positive or high-risk node-negative early-stage breast cancer, who received 4 cycles, at 21-day intervals, of nab-paclitaxel (100 mg/m² on days 1, 8, and 15) and cyclophosphamide (600 mg/m² on day 1). HER2 positive patients also received trastuzumab 8 mg/kg intravenous on cycle 1 day 1, followed by 6 mg/kg every 21 days for a total of 52 weeks. Full doses of all agents were administered in >90% of cycles. Grade 3/4 neutropenia was observed in 53% of the patients; however, only one episode of febrile neutropenia was observed in a total of 249 cycles administered. Other grade 3/4 toxicities (fatigue, nausea, vomiting, arthralgia/myalgia, peripheral neuropathy, and edema) were observed in less than 5% of patients. This combination of weekly nab-paclitaxel and cyclophosphamide with or without trastuzumab is feasible and well tolerated in patients with early stage breast cancer.

Robert et al performed another pilot study of dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel in patients with early breast cancer. In total, 30 patients received 4 cycles of dose-dense doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks with pegfilgrastim, followed by dose-dense 260 mg/m² nab-paclitaxel every 2 weeks (with pegfilgrastim given as needed). Twenty-nine of the 30 patients received nab-paclitaxel. Of the 29 patients, 27 (93.1%) patients received 4 cycles of nab-paclitaxel. Average and mean dose-intensity of nab-paclitaxel was 120.3 mg/m²/week and 127.7 mg/m²/week, respectively. During nab-paclitaxel therapy, 10 (34%) patients were treated with pegfilgrastim; 27 patients (90%) experienced peripheral neuropathy. However, the percentage of patients having <1 grade neuropathy at the end of treatment, 2 and 8 months after treatment were 59%, 79%, and 97%, respectively. Adjuvant dose-dense doxorubicin and cyclophosphamide followed by dose-dense nab-paclitaxel was feasible in patients with early breast cancer.
McArthur et al reported on a feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide followed by nab-paclitaxel in HER2-negative early-stage breast cancer.\(^4\) In this study, the authors evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin and cyclophosphamide followed by nab-paclitaxel. Eighty patients with normal left ventricular ejection fraction (LVEF) were enrolled. Baseline LVEF was 68%. LVEF at 2, 6, 9, and 18 months after treatment initiation were 68%, 64%, 63%, and 66%, respectively. One patient developed symptomatic LV dysfunction at month 15. Common adverse events necessitating treatment discontinuation were hypertension (4%), wound-healing complication (4%), and asymptomatic LVEF declines (4%). Bevacizumab with dose-dense doxorubicin and cyclophosphamide followed by nab-paclitaxel had a low rate of cardiac events.

These adjuvant studies mainly evaluated feasibility and tolerability of nab-paclitaxel in the adjuvant setting. Prospective randomized trials are needed to determine the benefit of incorporating nab-paclitaxel rather than standard taxane formulations, such as solvent-based paclitaxel and docetaxel, in the adjuvant settings.

The purpose of neoadjuvant chemotherapy is to downstage locally advanced cancer to facilitate curative operation, as well as to introduce breast-conserving surgery for operable but large tumors. Several neoadjuvant trials of nab-paclitaxel have been performed for locally advanced and operable breast cancer (Table 4).

Robidoux et al demonstrated the safety and efficacy of nab-paclitaxel, followed by an anthracycline-containing regimen as neoadjuvant chemotherapy, for locally advanced breast cancer patients regardless of hormone receptor or HER2 status.\(^4\) Sixty-six patients were enrolled, and 65 patients were analyzed in terms of response to this regimen. Patients received 100 mg/m\(^2\) of nab-paclitaxel weekly for 12 weeks and FEC (500 mg/m\(^2\) 5-FU, 100 mg/m\(^2\) epirubicin, 500 mg/m\(^2\) cyclophosphamide) every 21 days for 4 cycles. Patients with HER2-positive breast cancer received concomitant trastuzumab with nab-paclitaxel and FEC. When patients received trastuzumab, the epirubicin dose was reduced to 75 mg/m\(^2\). The pathological complete response (pCR) rate in the breast was 29% (19 out of 65 patients). For the HER2-positive subset, the pCR rate was 58% (11 out of 19 patients). This regimen was well tolerated without evidence of cardiac toxicity.

Yardley et al also showed the safety and efficacy of neoadjuvant dose-dense 3-drug combination therapy, nab-paclitaxel, epirubicin, and gemcitabine, together with pegfilgrastim support, for patients with locally advanced breast cancer.\(^4\) One hundred and twenty-three patients were enrolled, with 109 patients assessed in terms of tumor response. Patients received 6 doses of 2000 mg/m\(^2\) gemcitabine, 50 mg/m\(^2\) epirubicin, and 175 mg/m\(^2\) nab-paclitaxel, administered intravenously on day 1 every 14 days. Following each chemotherapy dose, 6 mg pegfilgrastim was administered subcutaneously on day 2. The pCR rate was

### Table 3: Adjuvant studies with nab-paclitaxel for breast cancer

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study design and setting</th>
<th>Treatment schedule</th>
<th>No. of pts.</th>
<th>Treatment received</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yardley et al</td>
<td>Pilot study Stage I–III</td>
<td>nab-P 100 mg/m(^2) (D1,8) + CPA 600 mg/m(^2) (D1) q3w +4 If HER2+, Tras 8 6 mg/kg q3w +52w</td>
<td>63</td>
<td>Discontinued nab-P/CPA: 2% nab-P omission: 15% nab-P reduction: 6%</td>
<td>Neutropenia: G3 37%, G4 16% Febrile neutropenia: G3 2% Fatigue: G3 5% Nausea: G3 2% Arthralgia/myalgias: G2 2% Peripheral neuropathy: G2 7%, G3 2%</td>
</tr>
<tr>
<td>Robert et al</td>
<td>Pilot study Stage I–III</td>
<td>AC q2w +4 → nab-P 260 mg/m(^2) q2w + G-CSF</td>
<td>29</td>
<td>Discontinued nab-P: 7% Average late dose intensity of nab-P: 92.5%</td>
<td>Neutropenia: G3 10%, G4 10% Febrile neutropenia: G3 0% Arthralgia/myalgias: G3 3% Peripheral neuropathy: G2 34%, G3 14% Febrile neutropenia: G3 4% Fatigue: G3 10% Peripheral neuropathy: G2 24%, G3 14% Headache: G3 8% Hypertension: G3 18%, G4 1% Cellulitis/wound-healing complication: G3 8%</td>
</tr>
<tr>
<td>McArthur et al</td>
<td>Phase II Stage I–III HER2-</td>
<td>AC q2w +4 → nab-P 260 mg/m(^2) q2w + G-CSF + Bev 10 mg/kg q2w + Bev 15 mg/kg q3w +8</td>
<td>80</td>
<td>Withdraw before completion of treatment: 33%</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** nab-P, nab-paclitaxel; No., number; CPA, cyclophosphamide; Tras, trastuzumab; q3w, every 3 weeks; q2w, every 2 weeks; G, grade; AC, doxorubicin + cyclophosphamide; G-CSF, granulocyte-colony stimulating factor; Bev, bevacizumab; pts, patients.
20% (23 out of 109 patients), with the estimated 3-year PFS and OS being 48% and 86%, respectively. Overall, this form of neoadjuvant chemotherapy was well tolerated.

Kaklamani et al conducted an interesting pilot neoadjuvant study in HER2-positive breast cancer which combined nab-paclitaxel and lapatinib, in an effort to avoid use of anthracycline, in patients with HER2-positive cancer.83 Thirty patients with stage I–III HER2-positive breast cancer were treated in the neoadjuvant setting with 1000 mg/day lapatinib and 260 mg/m² nab-paclitaxel every 3 weeks for 4 cycles. The ORR, which was the primary endpoint of this study, and the pCR rate were 82.8% and 17.9%, respectively. There was no significant drop in the left ventricular ejection fraction. Indeed, this regimen was well tolerated. No predictive factor of response was found in this study.

The results of these neoadjuvant trials are also somewhat promising in the metastatic setting, although the evidence is still quite modest in this respect. Phase III studies comparing nab-paclitaxel-containing regimens with a standard neoadjuvant regimen are needed to determine wider utility in the clinical setting.

### Safety

In a pivotal, randomized phase III trial in the metastatic setting, the toxicity of single agent nab-paclitaxel (260 mg/m² every 3 weeks) was compared with that mediated by CrEL-paclitaxel (175 mg/m² every 3 weeks) and the data are presented in Table 5. Treatment compliance of both groups was equally high with 96% (nab-paclitaxel) or 94% (CrEL-paclitaxel) of patients receiving 90% of the protocol-specified dose despite a higher dose-intensity of paclitaxel in the nab-paclitaxel group (85.1 mg/m²/week) than the CrEL-paclitaxel group (57.02 mg/m²/week). Treatment discontinuation, dose reduction and dose delay due to adverse events were also infrequent in both treatment groups. In addition, the safety profile of nab-paclitaxel was comparable to that of CrEL-paclitaxel although there were some differences between the two groups. Consistent with the safety data, no differences in quality of life (QOL) were observed between the two groups.

Grade 4 neutropenia was significantly lower in the nab-paclitaxel group than in the CrEL-paclitaxel group (9% vs 22%, respectively; \( P < 0.0001 \)) in a randomized phase III trial. The mean nadir of neutrophils was also significantly higher in the nab-paclitaxel group than that observed in the two groups.

Hypersensitivity reactions, such as dyspnea, flushing, chest pain, hypotension, and arrhythmia, can occur during infusion of drugs. Almost all patients treated with nab-paclitaxel received no premedication. On the other hand, 0.046. These findings suggest that the CrEL vehicle may be responsible for the noted toxicity in patients treated with CrEL-paclitaxel. Febrile neutropenia was uncommon in both treatment groups, as was severe anemia and thrombocytopenia. Hematologic toxicities were dose-dependent and reversible.

Hypersensitivity reactions, such as dyspnea, flushing, chest pain, hypotension, and arrhythmia, can occur during infusion of drugs. Almost all patients treated with nab-paclitaxel received no premedication. On the other hand,
almost all patients treated with CrEL-paclitaxel received premedication with corticosteroids and antihistamines to avoid hypersensitivity reaction. The incidence of this adverse event was low for both groups in the randomized trial. The incidence of severe hypersensitivity reaction was 2% in the CrEL-paclitaxel group despite their having received standard premedication.

Sensory neuropathy is a key toxic response in patients treated with paclitaxel. As expected, with a higher dose of paclitaxel, the incidence of a severe form of this toxic effect was greater in the nab-paclitaxel group than the CrEL-paclitaxel group (10% vs 2%, respectively; \( P < 0.001 \)), as well as the overall incidence of this toxicity (71% vs 56%, respectively; \( P < 0.05 \)), in the pivotal randomized comparative study. Fourteen out of 24 patients with severe sensory neuropathy in the nab-paclitaxel group improved after interruption of treatment in a median 22 days. Nab-paclitaxel-induced peripheral neuropathy could be managed with treatment interruption and dose reduction. The incidence of persistent severe sensory toxicity by 28 days after the first occurrence was equal in both groups. The sensory neuropathy was cumulatively dose dependent and partially reversible.

The incidence of myalgia and arthralgia was of a medium level and almost the same in both groups. These toxicities were usually transient, occurred 2 or 3 days after nab-paclitaxel administration, and resolved within a few days. Medium-level asthenia was also evident in both groups, albeit with only a low frequency of severe symptoms observed. The incidence of gastrointestinal disorders and fluid retention was also low in both groups.

By comparison, examination of triweekly nab-paclitaxel (300 mg/m²) with weekly nab-paclitaxel (100 mg/m² or 150 mg/m²) and triweekly docetaxel (100 mg/m²) in a randomized phase II trial (Table 6) showed neutropenia occurring more frequently and in a more severe manner in patients who received docetaxel. In particular, grade 4 neutropenia was significantly higher in patients treated with docetaxel (75%) compared with patients treated with nab-paclitaxel 100 mg/m² qw, 150 mg/m² qw, or 300 mg/m² q3w (5%, 9%, 5%, respectively; \( P < 0.001 \) for all three comparisons).

Consistent with these findings, the incidence of febrile neutropenia was significantly greater in the docetaxel group (8% vs 1% in each of the nab-paclitaxel groups). Among the three nab-paclitaxel groups, the incidence of all grades and grade 3 sensory neuropathy was higher in those groups with nab-paclitaxel 300 mg/m² triweekly or 150 mg/m² weekly compared with 100 mg/m² weekly. However, the level of severe sensory neuropathy in the nab-paclitaxel groups reduced more rapidly than in the docetaxel group (median time to improvement in grade 3 sensory neuropathy; triweekly 300 mg/m² nab-paclitaxel was 22 days, weekly 150 mg/m² nab-paclitaxel was 19 days, weekly 100 mg/m² nab-paclitaxel was 22 days, and triweekly docetaxel 100 mg/m² was 37 days).

### Table 5 Frequency of important adverse events: nab-paclitaxel 260 mg/m² versus CreL-paclitaxel 175 mg/m²

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Nab-paclitaxel (n = 229)</th>
<th>CrEL-paclitaxel (n = 225)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All grade</td>
<td>Grade 3</td>
</tr>
<tr>
<td>Hematologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>80%</td>
<td>34%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>12%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Anemia</td>
<td>47%</td>
<td>1%</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Infection</td>
<td>15%</td>
<td>4%</td>
</tr>
<tr>
<td>Nonhematologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity reaction</td>
<td>4%</td>
<td>0%</td>
</tr>
<tr>
<td>Sensory neuropathy</td>
<td>71%</td>
<td>10%</td>
</tr>
<tr>
<td>Myalgia/arthralgia</td>
<td>44%</td>
<td>8%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>47%</td>
<td>8%</td>
</tr>
<tr>
<td>GI toxicities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>29%</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>16%</td>
<td>2%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>25%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Mucositis</td>
<td>15%</td>
<td>2%</td>
</tr>
<tr>
<td>Fluid retention/edema</td>
<td>10%</td>
<td>0%</td>
</tr>
<tr>
<td>Injection site reaction</td>
<td>&lt;1%</td>
<td></td>
</tr>
</tbody>
</table>


Abbreviations: CreL, Cremophor EL®; GI, gastrointestinal.
Fatigue was also more common and severe in the docetaxel group than in the nab-paclitaxel groups. The frequency of arthralgia was higher in patients with nab-paclitaxel given 300 mg/m² triweekly and nab-paclitaxel 150 mg/m² given weekly compared with weekly nab-paclitaxel at 100 mg/m² and docetaxel. The frequency of severe toxicities was less in the weekly 100 mg/m² nab-paclitaxel compared with triweekly 300 mg/m² nab-paclitaxel and the weekly 150 mg/m² nab-paclitaxel. Several studies in the adjuvant setting were conducted to evaluate the tolerability of the nab-paclitaxel-containing regimen (Table 4). As a pilot study, Yardley et al reported adjuvant weekly nab-paclitaxel at 100 mg/m² on days 1, 8, and 15 in combination with cyclophosphamide at 600 mg/m² on day 1 every 3 weeks. If HER2 positive, patients received triweekly trastuzumab. Sixty-two patients were enrolled in this adjuvant pilot study, which had a low rate of discontinuation and dose reduction for this treatment.47

Although dose-dense nab-paclitaxel and bevacizumab combination was not feasible in the metastatic setting, adjuvant dose-dense doxorubicin and cyclophosphamide followed by nab-paclitaxel in combination with bevacizumab showed acceptable toxicity with low cardiac events.45 However, the discontinuation rate of this pilot study was not low (33%). Evaluation of safety and efficacy in the adjuvant setting is too limited. Large, randomized phase III studies to evaluate the efficacy and safety, especially long-term toxicity, of nab-paclitaxel are needed.

### Table 6: Frequency of adverse events in >25% of patients in randomized phase II trial: nab-paclitaxel 300 mg/m² q3w vs nab-paclitaxel 150 mg/m² qw vs nab-paclitaxel 100 mg/m² q3w vs docetaxel 100 mg/m² q3w

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Nab-paclitaxel 300 mg/m² q3w (n = 76)</th>
<th>Nab-paclitaxel 100 mg/m² qw (n = 76)</th>
<th>Nab-paclitaxel 150 mg/m² qw (n = 74)</th>
<th>Docetaxel 100 mg/m² q3w (n = 74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia</td>
<td>All grade 93%</td>
<td>80%</td>
<td>91%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>&gt;Grade 3 44%</td>
<td>25%</td>
<td>44%</td>
<td>94%</td>
</tr>
<tr>
<td>Alopecia</td>
<td>All grade 58%</td>
<td>76%</td>
<td>64%</td>
<td>71%</td>
</tr>
<tr>
<td></td>
<td>&gt;Grade 3 0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Sensory neuropathy</td>
<td>All grade 73%</td>
<td>58%</td>
<td>68%</td>
<td>61%</td>
</tr>
<tr>
<td></td>
<td>&gt;Grade 3 17%</td>
<td>8%</td>
<td>14%</td>
<td>12%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>All grade 36%</td>
<td>34%</td>
<td>45%</td>
<td>55%</td>
</tr>
<tr>
<td></td>
<td>&gt;Grade 3 5%</td>
<td>0%</td>
<td>3%</td>
<td>19%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>All grade 32%</td>
<td>19%</td>
<td>35%</td>
<td>22%</td>
</tr>
<tr>
<td></td>
<td>&gt;Grade 3 1%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Fatigue was also more common and severe in the docetaxel group than in the nab-paclitaxel groups. The frequency of arthralgia was higher in patients with nab-paclitaxel given 300 mg/m² triweekly and nab-paclitaxel 150 mg/m² given weekly compared with weekly nab-paclitaxel at 100 mg/m² and docetaxel. The frequency of severe toxicities was less in the weekly 100 mg/m² nab-paclitaxel compared with triweekly 300 mg/m² nab-paclitaxel and the weekly 150 mg/m² nab-paclitaxel. Several studies in the adjuvant setting were conducted to evaluate the tolerability of the nab-paclitaxel-containing regimen (Table 4). As a pilot study, Yardley et al reported adjuvant weekly nab-paclitaxel at 100 mg/m² on days 1, 8, and 15 in combination with cyclophosphamide at 600 mg/m² on day 1 every 3 weeks. If HER2 positive, patients received triweekly trastuzumab. Sixty-two patients were enrolled in this adjuvant pilot study, which had a low rate of discontinuation and dose reduction for this treatment.47

Although dose-dense nab-paclitaxel and bevacizumab combination was not feasible in the metastatic setting, adjuvant dose-dense doxorubicin and cyclophosphamide followed by nab-paclitaxel in combination with bevacizumab showed acceptable toxicity with low cardiac events.45 However, the discontinuation rate of this pilot study was not low (33%). Evaluation of safety and efficacy in the adjuvant setting is too limited. Large, randomized phase III studies to evaluate the efficacy and safety, especially long-term toxicity, of nab-paclitaxel are needed.

### Table 7: Comparison between nab-paclitaxel and cremophor-based paclitaxel

<table>
<thead>
<tr>
<th></th>
<th>Nab-paclitaxel</th>
<th>CrEL-paclitaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premedication</td>
<td>Unnecessary</td>
<td>Necessary</td>
</tr>
<tr>
<td>In-line filter</td>
<td>Unnecessary</td>
<td>Necessary</td>
</tr>
<tr>
<td>Time of intravenous</td>
<td>30 minutes</td>
<td>Weekly: 60 minutes</td>
</tr>
<tr>
<td>infusion</td>
<td>Triweekly: 180 minutes</td>
<td>Weekly: 80–100 mg/m²</td>
</tr>
<tr>
<td>Administration</td>
<td>Weekly: 100–150 mg/m²</td>
<td>Weekly: 175 mg/m²</td>
</tr>
<tr>
<td>Administration</td>
<td>Triweekly: 260 mg/m²</td>
<td>Impossible</td>
</tr>
<tr>
<td>dose</td>
<td>Possible</td>
<td></td>
</tr>
<tr>
<td>for patients with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hypersensitivity for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>alcohol</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** CrEL: Cremophor EL®.

**Approval of nab-paclitaxel**

Nab-paclitaxel was initially approved by the US Food and Drug Administration on 7th January 2005 and indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, when prior therapy should have included an anthracycline unless clinically contraindicated. As of March 2011, nab-paclitaxel was approved in 42 countries including EU, Canada, India, and Japan.

### Conclusion

Nab-technology can be used as an effective and novel drug delivery system: nab-paclitaxel (a nanoparticle-based formulation of paclitaxel encapsulated by albumin coating
instead of CrEL) has increased both the efficacy and safety of paclitaxel. Nab-paclitaxel has also several advantages over CrEL-paclitaxel, such as no need for premedication, special infusion set with in-line filter and alcohol, short infusion time, and high dose administration (Table 7). Nab-paclitaxel can improve the pharmacokinetic parameters of paclitaxel including the facilitating of dose-dependent linear pharmacokinetics, large volume of distribution, and large amount of free paclitaxel, thereby resulting in higher levels of drug delivery to the tumor compared with CrEL-paclitaxel. This is responsible for the increased antitumor effect. Clinical trials have demonstrated that single agent nab-paclitaxel displays high antitumor activity and manageable toxicity for patients with metastatic breast cancer. Phase I studies showed a higher MTD for nab-paclitaxel compared with CrEL-paclitaxel; the MTD of triweekly nab-paclitaxel was 300 mg/m² and the MTD of weekly nab-paclitaxel in heavily and lightly pretreated patients was 100 mg/m² and 150 mg/m², respectively. The DLTs observed were sensory neuropathy, stomatitis, and superficial keratopathy in patients treated with nab-paclitaxel 300 mg/m² every 3 weeks. The pivotal randomized phase III trial showed that the ORR and time to progression in patients treated with nab-paclitaxel were significantly better than those treated with CrEL-paclitaxel. The OS in patients receiving nab-paclitaxel was apparently greater, albeit with no significant difference, than that seen with patients receiving CrEL-paclitaxel. The safety profile was almost comparable in both groups even though the administration dose of paclitaxel used was higher, without premedication. Sensory neuropathy was significantly greater in the nab-paclitaxel group than in the CrEL-paclitaxel. However, the recovery time for sensory neuropathy was shortened in the nab-paclitaxel group.

The antitumor effect of triweekly nab-paclitaxel (300 mg/m²) was similar to triweekly docetaxel (100 mg/m²). But the tolerability of nab-paclitaxel was favorable compared with that of triweekly docetaxel. Weekly nab-paclitaxel displayed superior antitumor effects and less toxicity compared with triweekly docetaxel. The optimal treatment schedule was not confirmed. However, the weekly regimen in terms of efficacy and tolerability may be better than the triweekly regimen, and CrEL-paclitaxel, for HER2-negative breast cancer based on the results of a randomized phase III trial. Comparing paclitaxel alone with paclitaxel in combination with bevacizumab for metastatic breast cancer as first-line chemotherapy, nab-paclitaxel was used for a control arm for standard paclitaxel. On the other hand, the data relating to nab-paclitaxel treatment in the adjuvant and neoadjuvant settings have been limited even though preliminary results are promising. Therefore, the impact of prolonged recurrence-free and overall survival, as well as long-term toxicity, of a nab-paclitaxel-containing regimen has not been well elucidated. As nab-paclitaxel has higher efficacy and is well tolerated in the metastatic setting, prospective randomized trials of a nab-paclitaxel-containing regimen are urgently required to incorporate nab-paclitaxel rather than standard taxane, solvent-based paclitaxel and docetaxel, into the adjuvant and neoadjuvant settings.

**Disclosure**

The authors disclose no conflicts of interest.

**References**


